title: Vitamin D receptor: a highly versatile nuclear receptor.
abstract: Vitamin D receptor (VDR) modulators are used to treat hyperparathyroidism secondary to chronic kidney disease (CKD). The therapy is associated with reduced mortality in stage 5 CKD patients, who experience an extremely high cardiovascular disease (CVD)-related mortality rate. Chen et al. report that VDR is involved in regulating type A natriuretic peptide receptor (NPR-A) in inner medullary collecting duct cells. The regulation of NPR-A may be one of several mechanisms by which VDR activation reduces CVD risk in CKD.
authors.affiliation: Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, Illinois 60612-7230, USA. jrwuwong@uic.edu
authors.forename: J R
authors.initials: JR
authors.lastname: Wu-Wong
mesh_terms: D015090:25-Hydroxyvitamin D3 1-alpha-Hydroxylase / Q000378:metabolism; D000818:Animals; D002318:Cardiovascular Diseases / Q000209:etiology / Q000503:physiopathology; D002908:Chronic Disease; D006162:Guanylate Cyclase / Q000378:metabolism*; D006801:Humans; D007674:Kidney Diseases / Q000150:complications / Q000503:physiopathology; D051379:Mice; D018345:Mice, Knockout; D051381:Rats; D017461:Receptors, Atrial Natriuretic Factor / Q000378:metabolism*; D018167:Receptors, Calcitriol / Q000235:genetics / Q000502:physiology*; D018160:Receptors, Cytoplasmic and Nuclear / Q000502:physiology*
chemical_list: D018167:Receptors, Calcitriol; D018160:Receptors, Cytoplasmic and Nuclear; D015090:25-Hydroxyvitamin D3 1-alpha-Hydroxylase; D006162:Guanylate Cyclase; D017461:Receptors, Atrial Natriuretic Factor; C091715:atrial natriuretic factor receptor A